Methotrexate Injection Recalled Due to Lack of Sterility Assurance
Edge Pharma, LLC is recalling Methotrexate, USP, Sterile Solution for Injection (125 mg/5mL) due to lack of assurance of sterility. The recall affects 457 syringes distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable medication with lack of assurance of sterility, which creates a risk of serious harm (infections from non-sterile injection). The source text does not report any actual illnesses or injuries, making this a theoretical risk-of-harm scenario. Per the rubric, such cases score at most 3 (High).
Plain-English summary
Edge Pharma, LLC is recalling Methotrexate, USP, Sterile Solution for Injection (PF), 125 mg/5mL (2 mg/mL), 5 mL per syringe, NDC 05446-1505-05, due to lack of assurance of sterility.
The affected product consists of 457 syringes with lot numbers 09-2021-10@2 (dated 12/23/2021), 10-2021-21@2 (dated 02/01/2022), and 11-2021-09@5 (dated 02/21/2022). The product was distributed nationwide.
Methotrexate is an injectable medication, and use of a non-sterile product could result in serious infections. Patients who received this product should contact their healthcare provider immediately if they experience signs of infection.
The FDA is investigating this recall. Customers with questions may contact Edge Pharma, LLC at 856 Hercules Drive, Colchester, Vermont 05446.
The recalled product
- Product
- Methotrexate, USP, Sterile Solution for Injection (PF), 125 mg/5mL (2mg/mL), 5 mL per syringe, Edge Pharma, LLC, 856 Hercules Dr, Colchester, VT 05446, NDC 05446-1505-05
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Sterile Injectable
- Hazard
- lack-of-sterility
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- 09-2021-10@2 12/23/2021
- 10-2021-21@2 02/01/2022 & 11-2021-09@5 02/21/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27